17,261 trials
End-stage Renal Disease · Prevention of Thromboembolic Events · Hemodialysis
Primary: Cumulative Incidence Risk of the First Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) Events as Assessed by Blinded Central…
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24 — 37.3; 48.5; 54.8 percentage…
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Gastroparesis
Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05
Small Cell Lung Cancer (SCLC)
Primary: Overall Response Rate — 0; 9; 16; 7 Participants
Sickle Cell Disease
Primary: Double-Blind Treatment: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 6; 5; 5 Participants
Irritable Mood · Huntington's Disease
Primary: Tolerability of SRX246 — 25; 27; 30 Participants
Laryngeal Cancer
Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants
Lymphoma, T-Cell, Cutaneous
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Participants
Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate (ORR) — 3; 7 Participants
Tumors
Primary: Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib — 20; 20 milligram (mg)
SARS (Disease)
Primary: WHO(World Health Organization) COVID-19 Clinical Severity Scale — 2; 2 units on a scale
Sickle Cell Disease
Primary: Overall Incidence of Treatment Emergent Severe Adverse Events (SAE) — 15; 20 Participants — p=0.19
Cocaine Addiction
Primary: Cocaine Self-administration — 2.5; 4.8 cocaine choices/participant
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04